Finally, we examined ARPI treatment-related OS in the entire prostate adenocarcinoma cohort, which also revealed improved OS for patients with high FOLH1 expression (HR = 0.779, P < .001) (Figure 6B). The gene discussed is FOLH1; the disease is prostate adenocarcinoma.